Key points are not available for this paper at this time.
Introduction/Background The standard of care for treating advanced ovarian cancer is a combination of maximal effort cytoreductive surgery and chemotherapy. Survival rates following surgery for advanced ovarian cancer vary between different studies. A large study from the UK reported a mean overall survival of 37 months following surgery. The present study reports the mortality and morbidity data following maximal effort cytoreductive surgery in 139 patients treated in the Nottingham Cancer Centre 2014–2020. Methodology Data regarding patients undergoing maximal effort cytoreductive surgery between April 2014 and December 2020 were collected retrospectively and analysed using SPSS software. Kaplan-Meier survival curves were generated for mortality data. Local data was benchmarked and compared to the published literature. Results 139 cases were identified. The most common histological type was high grade serous cancer (68.3%), followed by clear cell adenocarcinoma. 72% of patients had stage 3 and 4 disease at presentation. The mean operative duration was 422 minutes and macroscopic cytoreduction was achieved in 84.9% of patients. A multimodal surgical approach included bowel resection (51%), stoma formation (31.6%), splenectomy (38.1%) and diaphragmatic peritonectomy (79%). The median length of stay in ITU was 2 days. Common complications were anaemia related to surgical blood loss requiring blood transfusion, infection and wound dehiscence. The 3-year OS of the patients in our cohort was 61% and the 5-year OS of patients operated between April 2014 and November 2018 was 50%. The median OS was 47 months. Median survival of cases where complete cytoreduction was achieved was 51 months; in cases of incomplete cytoreduction the median survival was 31 months. Conclusion Our data, in line with other published studies, emphasise the importance of maximal effort cytoreductive surgery as part of the treatment for patients with advanced ovarian cancer. We have shown survival and complication rates comparable to similar studies in this field. Disclosures Nothing to disclose.
Katsanevakis et al. (Fri,) studied this question.